IFNG and neoplasm: Expressed on tumor and immune cells, PD‐L1 binds to the PD‐1 receptor on activated T cells, B cells, and NK cells; this interaction inhibits T cell activation and proliferation, reduces effector cytokine production (e.g., IFN‐γ), and decreases T cell cytotoxic activity.